Alan S. Roemer

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Biotech fund

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

The Trout Group is the leading investor relations and strategic advisory firm serving the life sciences and clean technology industries. Since 1996, we have been providing companies with expert advice and access to the institutional investment community. With more than a decade of experience in the biotechnology, pharmaceuticals, medical technology, life science technology and clean technology sectors, we offer our clients the relationships and knowledge base needed to clarify investment themes and reach the proper audience. Our global reach extends through a network of offices and contacts in all major financial centers, helping our clients find the right investors. Trout is headquartered in New York, with satellite offices in Boston, San Francisco, London, and Shanghai. Why are we called the Trout Group? The name of our firm highlights our commitment to working together as a firm and with our clients. In classical music, the quintet is the quintessential illustration of teamwork. Each member is an integral part of the team and by working in unison, a small, talented, smart group can sound like a grand symphony. A favorite of firm founder Jonathan Fassberg is a piano quintet by Franz Schubert, popularly called the Trout Quintet – hence The Trout Group. Trout Capital LLC, a securities broker-dealer and member of FINRA and the SIPC, is an affiliate of The Trout Group LLC and the two companies share common ownership.

Bank of America is one of the worlds largest financial institutions, serving individuals, small- and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services. The company serves approximately 56 million U.S. consumer and small business relationships. It is among the worlds leading wealth management companies and is a global leader in corporate and investment banking and trading. This LinkedIn company page is moderated. For more information, please visit: https://bit.ly/32FDdQr. For account issues, please visit: https://bit.ly/2GeTIeP.